AU2021337687A1 - Nectin-4 antibodies and uses thereof - Google Patents
Nectin-4 antibodies and uses thereof Download PDFInfo
- Publication number
- AU2021337687A1 AU2021337687A1 AU2021337687A AU2021337687A AU2021337687A1 AU 2021337687 A1 AU2021337687 A1 AU 2021337687A1 AU 2021337687 A AU2021337687 A AU 2021337687A AU 2021337687 A AU2021337687 A AU 2021337687A AU 2021337687 A1 AU2021337687 A1 AU 2021337687A1
- Authority
- AU
- Australia
- Prior art keywords
- seq
- nectin
- antibody
- antibodies
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063074864P | 2020-09-04 | 2020-09-04 | |
| US63/074,864 | 2020-09-04 | ||
| US202163166622P | 2021-03-26 | 2021-03-26 | |
| US63/166,622 | 2021-03-26 | ||
| PCT/US2021/049014 WO2022051591A2 (en) | 2020-09-04 | 2021-09-03 | Nectin-4 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021337687A1 true AU2021337687A1 (en) | 2023-03-23 |
Family
ID=78080439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021337687A Pending AU2021337687A1 (en) | 2020-09-04 | 2021-09-03 | Nectin-4 antibodies and uses thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230331867A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4208259A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7851914B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230060509A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021337687A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3193584A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022051591A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114845740B (zh) | 2020-01-31 | 2026-06-02 | 先天制药公司 | 癌症的治疗 |
| AU2021276616A1 (en) * | 2020-05-20 | 2023-01-05 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 and uses thereof |
| KR20240136924A (ko) * | 2021-08-27 | 2024-09-19 | 씨에스피씨 메가리스 바이오파마슈티칼 씨오., 엘티디. | 항 Nectin-4 항체, 약물 접합체 및 이의 제조방법 및 용도 |
| CN116063498A (zh) * | 2022-04-27 | 2023-05-05 | 博际生物医药科技(杭州)有限公司 | 单域抗Nectin-4抗体 |
| WO2023227660A1 (en) * | 2022-05-25 | 2023-11-30 | Innate Pharma | Nectin-4 binding agents |
| JP2025523049A (ja) * | 2022-07-14 | 2025-07-17 | バイオ-テラ ソリュ-ションズ,エルティーディー. | 抗Nectin-4抗体及びその使用 |
| CN117982672A (zh) * | 2022-07-14 | 2024-05-07 | 百奥泰生物制药股份有限公司 | 抗Nectin-4抗体药物偶联物及应用 |
| IL318911A (en) * | 2022-09-20 | 2025-04-01 | Nectin Therapeutics Ltd | Humanized antibodies against NECTIN-4 and their drug conjugates |
| CN118871132A (zh) * | 2023-02-27 | 2024-10-29 | 石药集团巨石生物制药有限公司 | 重组人源化抗Nectin-4单抗-MMAE偶联药物的药物组合物 |
| JP7689606B2 (ja) * | 2023-06-20 | 2025-06-06 | イーライ リリー アンド カンパニー | ネクチン-4抗体及び抗体-薬物コンジュゲート |
| KR20250177512A (ko) * | 2024-06-14 | 2025-12-24 | 삼성바이오에피스 주식회사 | 신규한 항-넥틴-4 항체 및 이의 용도 |
| US20260167719A1 (en) * | 2024-12-17 | 2026-06-18 | Merck Sharp & Dohme Llc | Nectin-4 antibodies |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| EP0593592B1 (en) | 1991-07-08 | 1998-03-25 | The University Of Massachusetts At Amherst | Thermotropic liquid crystal segmented block copolymer |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| CN1399645A (zh) | 1999-07-29 | 2003-02-26 | 米德列斯公司 | Her2/neu的人单克隆抗体 |
| US7271240B2 (en) | 2001-03-14 | 2007-09-18 | Agensys, Inc. | 125P5C8: a tissue specific protein highly expressed in various cancers |
| US20040081653A1 (en) | 2002-08-16 | 2004-04-29 | Raitano Arthur B. | Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| PE20090245A1 (es) | 2007-05-08 | 2009-03-17 | Genentech Inc | Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos |
| BRPI0818780A2 (pt) | 2007-10-19 | 2015-04-22 | Genentech Inc | Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos |
| CA3220104A1 (en) | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| ES2874306T3 (es) | 2010-09-29 | 2021-11-04 | Agensys Inc | Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12 |
| CN102469482A (zh) | 2010-11-12 | 2012-05-23 | 中兴通讯股份有限公司 | 一种广播控制信道信息倒换方法及系统 |
| EP2729898A1 (en) | 2011-07-10 | 2014-05-14 | Blendology Limited | An electronic data sharing device and method of use |
| WO2013063391A2 (en) | 2011-10-28 | 2013-05-02 | Trianni, Inc. | Transgenic animals and methods of use |
| CA2858806A1 (en) | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of polypeptides |
| CN104640572B (zh) | 2012-05-15 | 2018-04-27 | 索伦托医疗有限公司 | 药物偶联物,偶联方法,及其用途 |
| US9738724B2 (en) | 2012-06-08 | 2017-08-22 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| NO2789793T3 (cg-RX-API-DMAC7.html) | 2012-10-24 | 2018-01-27 | ||
| EP2916872B1 (en) | 2012-11-09 | 2019-02-27 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
| WO2014202773A1 (en) | 2013-06-20 | 2014-12-24 | Innate Pharma | Enzymatic conjugation of polypeptides |
| KR20160042871A (ko) | 2013-06-21 | 2016-04-20 | 이나뜨 파르마, 에스.아. | 폴리펩티드의 효소적 콘쥬게이션 |
| PL2845550T3 (pl) | 2013-09-10 | 2017-08-31 | Erbe Elektromedizin Gmbh | Instrument chirurgiczny z trzonem z tworzywa sztucznego |
| CA2951887A1 (en) | 2014-06-12 | 2015-12-17 | Cspc Dophen Corporation | Homogenous antibody drug conjugates via enzymatic methods |
| HUE049325T2 (hu) | 2014-08-28 | 2020-09-28 | Pfizer | Stabilitás modulátor linker antitest-hatóanyag konjugátumokhoz történõ alkalmazásra |
| JP6817288B2 (ja) | 2015-08-10 | 2021-01-20 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. | 新規な連結体及び生体分子と薬物との特異的共役におけるその使用 |
| WO2017035252A1 (en) | 2015-08-24 | 2017-03-02 | Trianni, Inc. | Enhanced production of immunoglobulins |
| EP3347048B1 (en) | 2015-09-09 | 2020-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to nectin-4 and uses thereof |
| CN108472386A (zh) | 2015-10-02 | 2018-08-31 | 百时美施贵宝公司 | 用于缀合抗体的转谷氨酰胺酶变体 |
| KR20190014525A (ko) | 2016-05-27 | 2019-02-12 | 애브비 바이오테라퓨틱스 인크. | 면역 조절 단백질과 종양 항원을 결합하는 이중특이적 결합 단백질 |
| WO2018140590A1 (en) | 2017-01-25 | 2018-08-02 | Massachusetts Institute Of Technology | Seft-labeling miniproteins and conjugates comprising them |
| US11274160B2 (en) | 2017-03-02 | 2022-03-15 | INSERM (Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to Nectin-4 and uses thereof |
| KR20210125094A (ko) | 2017-04-06 | 2021-10-15 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 비스-링키지를 사용한 세포독성 약물의 접합 |
| TWI870338B (zh) | 2017-06-05 | 2025-01-21 | 美商艾澤西公司 | 粘附分子-4結合蛋白及其使用方法 |
| WO2019215782A1 (ja) | 2018-05-07 | 2019-11-14 | Hiyama Kazuhiro | 診断情報提供装置、方法及びシステム |
| US12077583B2 (en) | 2018-05-09 | 2024-09-03 | Nectin Therapeutics Ltd. | Antibodies specific to human NECTIN4 |
-
2021
- 2021-09-03 KR KR1020237009723A patent/KR20230060509A/ko active Pending
- 2021-09-03 AU AU2021337687A patent/AU2021337687A1/en active Pending
- 2021-09-03 WO PCT/US2021/049014 patent/WO2022051591A2/en not_active Ceased
- 2021-09-03 CA CA3193584A patent/CA3193584A1/en active Pending
- 2021-09-03 EP EP21787105.2A patent/EP4208259A2/en active Pending
- 2021-09-03 US US18/024,465 patent/US20230331867A1/en active Pending
- 2021-09-03 JP JP2023514862A patent/JP7851914B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20230331867A1 (en) | 2023-10-19 |
| WO2022051591A2 (en) | 2022-03-10 |
| JP7851914B2 (ja) | 2026-04-27 |
| EP4208259A2 (en) | 2023-07-12 |
| JP2023540526A (ja) | 2023-09-25 |
| CA3193584A1 (en) | 2022-03-10 |
| KR20230060509A (ko) | 2023-05-04 |
| WO2022051591A3 (en) | 2022-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230331867A1 (en) | Nectin-4 antibodies and uses thereof | |
| US12460005B2 (en) | Binding molecules specific for claudin 18.2, compositions and methods thereof, for treatment of cancer and other diseases | |
| US20230272063A1 (en) | Anti-claudin 18 antibodies and methods of use thereof | |
| JP2024532485A (ja) | Cd137および腫瘍関連抗原に結合する二重特異性結合タンパク質 | |
| US20250277026A1 (en) | Antibodies against claudin-6 and uses thereof | |
| AU2013369339B2 (en) | Anti-LAMP1 antibodies and antibody drug conjugates, and uses thereof | |
| KR20160097336A (ko) | 신규 항-dpep3 항체 및 이의 사용 방법 | |
| KR20160070191A (ko) | 신규한 항-클라우딘 항체 및 사용 방법 | |
| CN113382750A (zh) | Cdcp1靶向疗法 | |
| US20220153863A1 (en) | Prame binding molecules and uses thereof | |
| KR20250152073A (ko) | 항체, 항원 결합 단편 및 사용 방법 | |
| CN116507641A (zh) | 结合素-4抗体及其用途 | |
| CN117597362A (zh) | 抗紧密连接蛋白-6的抗体及其用途 | |
| US20260078179A1 (en) | Cdh17 antibodies and uses thereof | |
| HK40098610A (en) | Nectin-4 antibodies and uses thereof | |
| HK40107987A (en) | Antibodies against claudin-6 and uses thereof | |
| CN118165107A (zh) | 结合tigit的抗体分子 | |
| CN118234511A (zh) | 与cd137和肿瘤相关抗原结合的双特异性结合蛋白 | |
| HK40064186A (en) | Anti-claudin 18 antibodies and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: CSPC MEGALITH BIOPHARMACEUTICAL CO., LTD., Free format text: FORMER APPLICANT(S): NOVAROCK BIOTHERAPEUTICS, LTD. |